ARTICLE | Clinical News
Votrient pazopanib: Preliminary Phase II data
October 18, 2010 7:00 AM UTC
Researchers at the Fondazione IRCCS Istituto Nazionale dei Tumori reported preliminary data from 18 patients in an ongoing, open-label, Italian Phase II trial showing that once-daily 800 mg oral pazop...